Core Insights - Jasper Therapeutics, Inc. reported updated data from the BEACON Phase 1b/2a study of briquilimab, showing high efficacy in treating chronic spontaneous urticaria (CSU) with 89% of participants in the 240mg and 360mg cohorts achieving a complete response [1][5] - The study faced confounding results due to issues with a specific drug product lot, prompting an investigation and a halt in the ETESIAN asthma study [2][4] - The company plans to transition affected patients to a new drug product and enroll additional participants to strengthen the data set for the upcoming Phase 2b study [3][5] Study Results - In the BEACON study, 8 of 9 participants (89%) in the 240mg and 360mg single-dose cohorts achieved a complete response, while 73% of participants in the 180mg Q8W open-label extension study achieved a complete response at 12 weeks [1][11] - The 240mg Q8W and 240mg followed by 180mg Q8W cohorts showed confounding results due to the drug product lot issue, with 10 of 13 patients affected [2][5] - Substantial reductions in UAS7 scores were observed, with a mean change of 28.3 points in the 240mg single-dose cohort and 22.9 points in the 360mg single-dose cohort [10] Safety and Tolerability - No grade 3 or higher treatment-related adverse events were reported, indicating a favorable safety profile for briquilimab [1][13] - Mild and predictable decreases in neutrophil counts were observed, but these resolved during the study without leading to discontinuations [13] Future Plans - The company is investigating the drug product lot issue and expects results in the coming weeks, while also planning to enroll an additional 10-12 patients in the affected cohorts [2][3] - The commencement of the Phase 2b study is now expected in mid-2026, with data from additional BEACON patients anticipated in Q4 2025 [3][5] Company Overview - Jasper Therapeutics focuses on developing briquilimab, a monoclonal antibody targeting mast cell-driven diseases such as CSU and chronic inducible urticaria (CIndU) [16][17] - The company aims to address the underlying inflammatory responses in these conditions through its innovative therapeutic approach [16]

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] - The company announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, highlighting initial clinical data from the SPOTLIGHT Phase 1b/2a study [1][2] Presentation Details - The first abstract discusses initial results from the SPOTLIGHT study on briquilimab in adults with CIndU who remain symptomatic despite H-1 antihistamine treatment, scheduled for presentation on June 14 [2] - The second abstract presents findings on briquilimab's efficacy in protecting against relapse of dermatitis in a mouse model, also scheduled for June 14 [2] - The third abstract reports updated results showing briquilimab's rapid and clinically meaningful disease control in adults with CSU, to be presented on June 15 [2] - The fourth abstract focuses on briquilimab's effects on mitigating COPD-like features in an asthma model, scheduled for presentation on June 15 [2] Company Overview - Jasper is developing briquilimab as a targeted aglycosylated monoclonal antibody that inhibits signaling through the c-Kit receptor, leading to mast cell depletion and addressing inflammatory responses in mast cell driven diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU and CIndU [3]

Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT to treat mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] Product Development - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the cell-surface receptor KIT, leading to the depletion of mast cells through apoptosis, which addresses the inflammatory response in mast cell driven diseases [2] - The company is currently conducting clinical studies of briquilimab for patients with CSU, CIndU, or asthma, demonstrating efficacy and safety in previous trials [2] Investor Engagement - Jasper Therapeutics will participate in the RBC Capital Markets 2025 Global Healthcare Conference on May 21, 2025, and the Jefferies 2025 Global Healthcare Conference on June 5, 2025, with live webcasts available on their Investor Relations website [1]

Core Insights - Jasper Therapeutics is advancing briquilimab, a novel antibody therapy targeting mast cell-driven diseases, with significant progress reported in clinical trials [2][5][7] - The company reported a net loss of $21.2 million for the first quarter of 2025, with a basic and diluted net loss per share of $1.41 [6][10] Clinical Development - Jasper is focused on three clinical programs: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, with important data readouts expected later in 2025 [2][5] - The BEACON study in CSU continues to show promising results, with updated data presented at major allergy meetings [2][5] - Enrollment in the BEACON Phase 1b/2a study is ongoing, with additional data expected in Q3 2025 [5] - The SPOTLIGHT study for CIndU has completed enrollment in its final cohort, with data presentation planned for June 2025 [5] - The ETESIAN study for asthma is also enrolling patients, with initial data anticipated in the second half of 2025 [5] Financial Performance - As of March 31, 2025, Jasper had cash and cash equivalents totaling $48.8 million, down from $71.6 million at the end of 2024 [5][12] - Research and development expenses for Q1 2025 were $16.2 million, while general and administrative expenses were $5.6 million [5][10] - Total operating expenses for the first quarter were $21.8 million, compared to $15.1 million in the same period of 2024 [10]